Clene Inc.

NASDAQ:CLNN

Biotechnology

Healthcare
$3.66 +1.35%

+$0.08 today

Market cap
$52.70M
Beta
0.92
P/E (TTM)
-2.1
EPS (TTM)
-$2.88
52W Low $3.25High $13.50

Volume 0.12M

Average 0.50M

CLNN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Clene Inc.NASDAQ: CLNN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA turns negative

Q1 FY2026 EBITDA was -$6.94M, compared with $261K a year earlier. Trailing-twelve-month EBITDA was -$29.2M.

Context

  • EBITDA amounted to 10998.0% of revenue in FY2025, up 1146.8 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$16.37M (+25.6%) for the fiscal year ending Dec 2026, a slowdown from the +34.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.94M+14.5% QoQ
Last fiscal yearDec 2025
-$22M+34.7% YoY
LTMMar 2026
-$29.2M-21.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2760.9%+31.8%+2792.7 pp
1 year+34.7%+25.6%-9.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(22M) USD
Year-over-year change
+34.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CLNN compares with its peers on the latest reported figures

  • CLNN's LTM Mar 2026 EBITDA of -$29.2M is the 4th highest of the 11 companies compared; the peer median is -$48.43M.
  • Its year-over-year change of -21.6% is the 8th highest of 11, against a peer median of +0.4%.
  • EBITDA amounts to 21792.5% of revenue for CLNN, versus a peer median of 337.0%.
CLNN Competitors Peer median
EBITDA for CLNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$78.84M +1391.3%——
COYACoya Therapeutics, Inc.LTM Mar 2026-$21.1M -18.3%—265.8%
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24M +7.8%—337.0%
CLNNClene Inc.LTM Mar 2026-$29.2M -21.6%—21792.5%
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.18M -45.5%——
STTKShattuck Labs, Inc.LTM Mar 2026-$46.23M +30.8%—4623.1%
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M -7.0%—32.2%
CNTBConnect Biopharma Holdings LimitedFY2025-$54.58M -270.2%—85279.7%
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$107.98M +49.6%——
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$115.78M -490.7%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$130.98M +37.9%——
Peer median (excluding CLNN) -$48.43M+0.4%—337.0%

Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue723K473K654K342K200K
Cost of Revenue289K26K121K70K43K
Gross Profit434K447K533K272K157K
Gross Margin60.0%94.5%81.5%79.5%78.5%
Research & Development28.42M31.92M26.66M20.06M14.01M
Selling, General & Admin18.81M16.16M14.42M13.31M9.23M
Operating Expenses50.41M48.86M41.07M33.37M23.24M
Depreciation & Amortization955K1.02M1.71M1.65M1.5M
EBITDA(8.34M)(25.6M)(43.24M)(33.69M)(22M)
EBITDA Margin-1153.9%-5412.9%-6611.8%-9851.2%-10998.0%
Operating Income(49.98M)(48.41M)(40.54M)(33.09M)(23.08M)
Operating Margin-6912.6%-10234.5%-6198.8%-9676.3%-11541.5%
Interest Income001.39M865K223K
Interest Expense870K3.3M4.56M4.06M2.68M
Other Income / Expenses39.81M18.49M(8.96M)(6.31M)(3.09M)
Income Before Tax(10.17M)(29.92M)(49.5M)(39.4M)(26.17M)
Pre-Tax Margin-1406.4%-6325.2%-7569.4%-11520.5%-13086.5%
Income Tax Expense(428K)0000
Net Income(9.74M)(29.92M)(49.5M)(39.4M)(26.17M)
Net Margin-1347.2%-6325.2%-7569.4%-11520.5%-13086.5%
EPS (Basic)(3.16)(4.69)(9.43)(5.67)(2.65)
EPS (Diluted)(3.16)(4.69)(9.43)(5.67)(2.65)
Weighted Avg Shares3.08M3.26M5.25M6.95M9.86M
Weighted Avg Shares (Diluted)3.08M3.26M5.25M6.95M9.86M

Clene Inc.

NASDAQ:CLNN

Intrinsic Alpha fair value

Locked

Current Price

$3.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.